The Zhitong Finance App learned that Citibank released a research report stating that Hanson Pharmaceuticals (03692.HK)'s innovative drug development strategy continues to advance, and management expects Ameile (Ameile) sales to continue to grow, and existing innovative drugs will gradually be released; as new indications and new products are added one after another, the growth performance in 2028 is expected to be stronger than 2027. The bank maintains Hanson Pharmaceuticals's “buy” rating, with a target price of HK$52.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.